Incyte Corp. INCY
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $5.1B | +21% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $1.5B | +2369% | FY ending Dec 31, 2025 |
| Net income | $1.3B | +3845% | FY ending Dec 31, 2025 |
| Earnings per share | $6.41 | +4173% | FY ending Dec 31, 2025 |
| Research & development | $2.1B | -21% | FY ending Dec 31, 2025 |
| Cash from operations | $1.4B | +322% | FY ending Dec 31, 2025 |
| Share buybacks | $0 | -100% | FY ending Dec 31, 2025 |
| Cash | $3.1B | +84% | FY ending Dec 31, 2025 |
| Long-term debt | $19.1B | +71146% | FY ending Dec 31, 2018 |
| Shareholders' equity | $5.2B | +50% | FY ending Dec 31, 2025 |
| Shares outstanding | 198M | +3% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 35 sales ($58.3M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 2,642 | $112.71 | $298K | Oct 15, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold2 fills | 23,218 | $120.49 avg | $2.8M | Sep 15, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 10,801 | $125.56 | $1.4M | Aug 19, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 10,803 | $120.04 | $1.3M | Aug 12, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 10,640 | $122.69 | $1.3M | Aug 5, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Sold | 2,207 | $123.99 | $274K | Aug 5, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Sold | 6,055 | $120.43 | $729K | Aug 3, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Sold11 fills | 41,899 | $119.46 avg | $5.0M | Jul 31, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 15,888 | $119.70 | $1.9M | Jul 31, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Sold | 1,877 | $114.73 | $215K | Jul 16, 2026 |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | Sold | 1,093 | $115.01 | $126K | Jul 16, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Sold | 28,237 | $113.05 | $3.2M | Jul 15, 2026 |
| Thomas TrayPrincipal Accounting Officer | Sold | 2,639 | $100.00 | $264K | Jun 4, 2026 |
| Thomas TrayPrincipal Accounting Officer | Sold | 2,051 | $97.35 | $200K | May 26, 2026 |
| Paul J ClancyDirector | Sold | 15,000 | $94.93 | $1.4M | May 19, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Sold | 18,667 | $96.50 | $1.8M | Apr 17, 2026 |
| Pablo J CagnoniPresident, R&D | Sold | 18,667 | $94.24 | $1.8M | Mar 17, 2026 |
| Pablo J CagnoniPresident, R&D | Sold | 18,668 | $100.91 | $1.9M | Feb 19, 2026 |
| Mohamed Khairie IssaEVP, Head of US Oncology | Sold | 10,856 | $109.07 | $1.2M | Jan 7, 2026 |
| Steven H SteinEVP & Chief Medical Officer | Sold | 15,634 | $101.70 | $1.6M | Jan 5, 2026 |
| Thomas TrayPrincipal Accounting Officer | Sold | 2,774 | $100.00 | $277K | Dec 19, 2025 |
| Thomas TrayPrincipal Accounting Officer | Sold | 600 | $98.25 | $59K | Dec 18, 2025 |
| Michael James MorrisseyEVP, Head of Tech. Operations | Sold | 4,323 | $97.26 | $420K | Dec 17, 2025 |
| Michael James MorrisseyEVP, Head of Tech. Operations | Sold2 fills | 54,008 | $97.29 avg | $5.3M | Dec 16, 2025 |
| Patrick A MayesEVP & Chief Scientific Officer | Sold | 255 | $94.94 | $24K | Dec 11, 2025 |
| Patrick A MayesEVP & Chief Scientific Officer | Sold | 5,553 | $95.58 | $531K | Dec 10, 2025 |
| Steven H SteinEVP & Chief Medical Officer | Sold | 20,105 | $102.51 | $2.1M | Dec 2, 2025 |
| Steven H SteinEVP & Chief Medical Officer | Sold | 2,559 | $102.96 | $263K | Dec 1, 2025 |
| Thomas TrayPrincipal Accounting Officer | Sold | 600 | $103.00 | $62K | Nov 24, 2025 |
| Thomas TrayPrincipal Accounting Officer | Sold | 169 | $102.00 | $17K | Nov 21, 2025 |
| Sheila A. DentonEVP & General Counsel | Sold | 278 | $104.36 | $29K | Nov 17, 2025 |
| Herve HoppenotDirector | Sold | 187,500 | $105.46 | $19.8M | Nov 10, 2025 |
| Steven H SteinEVP & Chief Medical Officer | Sold | 5,233 | $102.20 | $535K | Nov 5, 2025 |
| Sheila A. DentonEVP & General Counsel | Sold | 598 | $101.36 | $61K | Nov 4, 2025 |
| Lee HeesonEVP, Head of Incyte Intl | Sold | 3,074 | $94.02 | $289K | Nov 3, 2025 |
Other insider moves (79): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pablo J CagnoniPresident, Global Head of R&D | Option exercise4 fills | 2,642 | $65.76 avg | $174K | Oct 15, 2026 |
| Lee HeesonEVP, Head of Incyte Intl | Tax withholding | 463 | $117.14 | $54K | Oct 1, 2026 |
| Edmund HarriganDirector | Awardpre-set plan | 206 | $121.35 | $25K | Sep 30, 2026 |
| Paul J ClancyDirector | Awardpre-set plan | 203 | $121.35 | $25K | Sep 30, 2026 |
| Baker Bros. Advisors LpDirector, 10% owner | Award2 fills | 644 | – | – | Sep 30, 2026 |
| David H GardnerEVP, Chief Strategy Officer | Tax withholding | 920 | $126.93 | $117K | Sep 22, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Option exercise4 fills | 23,218 | $66.39 avg | $1.5M | Sep 15, 2026 |
| Ramitpal K BasiEVP, Human Resources | Tax withholding | 504 | $129.72 | $65K | Aug 25, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Option exercise | 2,207 | $106.47 | $235K | Aug 5, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Option exercise | 6,055 | $105.43 | $638K | Aug 3, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Option exercise15 fills | 39,712 | $74.37 avg | $3.0M | Jul 31, 2026 |
| Thomas TrayPrincipal Accounting Officer | Award | 2,834 | – | – | Jul 16, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Award | 9,798 | – | – | Jul 16, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Award | 5,916 | – | – | Jul 16, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Award | 13,403 | – | – | Jul 16, 2026 |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | Award | 7,857 | – | – | Jul 16, 2026 |
| Ramitpal K BasiEVP, Human Resources | Award | 4,991 | – | – | Jul 16, 2026 |
| David H GardnerEVP, Chief Strategy Officer | Award | 7,395 | – | – | Jul 16, 2026 |
| Richard A. HoffmanEVP & General Counsel | Award | 7,395 | – | – | Jul 16, 2026 |
| William MeuryChief Executive Officer, Director | Award | 26,807 | – | – | Jul 16, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Tax withholding | 4,950 | $115.09 | $570K | Jul 15, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Tax withholding | 3,088 | $115.09 | $355K | Jul 15, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Tax withholding | 1,512 | $115.09 | $174K | Jul 15, 2026 |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | Tax withholding | 1,099 | $115.09 | $126K | Jul 15, 2026 |
| Thomas TrayPrincipal Accounting Officer | Tax withholding | 1,098 | $115.09 | $126K | Jul 15, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Tax withholding | 21,830 | $114.88 | $2.5M | Jul 14, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Tax withholding | 17,969 | $114.88 | $2.1M | Jul 14, 2026 |
| Thomas TrayPrincipal Accounting Officer | Tax withholding | 692 | $114.88 | $79K | Jul 14, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Tax withholding | 437 | $114.88 | $50K | Jul 14, 2026 |
| William MeuryChief Executive Officer, Director | Tax withholding | 4,779 | $116.86 | $558K | Jul 2, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Tax withholding | 2,177 | $116.86 | $254K | Jul 2, 2026 |
| Thomas TrayPrincipal Accounting Officer | Tax withholding | 477 | $116.86 | $56K | Jul 2, 2026 |
| Patrick A MayesEVP & Chief Scientific Officer | Tax withholding | 350 | $116.86 | $41K | Jul 2, 2026 |
| Edmund HarriganDirector | Awardpre-set plan | 255 | $113.36 | $29K | Jun 30, 2026 |
| Paul J ClancyDirector | Awardpre-set plan | 252 | $113.36 | $29K | Jun 30, 2026 |
| Baker Bros. Advisors LpDirector, 10% owner | Award2 fills | 800 | – | – | Jun 30, 2026 |
| Baker Bros. Advisors LpDirector, 10% owner | Award2 fills | 3,284 | – | – | Jun 8, 2026 |
| Edmund HarriganDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Paul J ClancyDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Jacqualyn A FouseDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Jean Jacques BienaimeDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Katherine A HighDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Otis W BrawleyDirector | Award | 1,642 | – | – | Jun 8, 2026 |
| Thomas TrayPrincipal Accounting Officer | Option exercise | 2,639 | $83.83 | $221K | Jun 4, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Tax withholding | 25,469 | $95.59 | $2.4M | Jun 1, 2026 |
| Jean Jacques BienaimeDirector | Tax withholding | 13,059 | $97.10 | $1.3M | May 26, 2026 |
| Jean Jacques BienaimeDirector | Option exercise | 15,000 | $84.53 | $1.3M | May 26, 2026 |
| Paul J ClancyDirector | Option exercise | 15,000 | $84.53 | $1.3M | May 19, 2026 |
| Baker Bros. Advisors LpDirector, 10% owner | Option exercise2 fills | 30,000 | $84.53 avg | $2.5M | May 8, 2026 |
| Suketu UpadhyayEVP & Chief Financial Officer | Award | 26,343 | – | – | May 4, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Option exercise2 fills | 18,667 | $69.43 avg | $1.3M | Apr 17, 2026 |
| William MeuryChief Executive Officer, Director | Option exercise | 125,000 | – | – | Apr 15, 2026 |
| Pablo J CagnoniPresident, Global Head of R&D | Award | 27,892 | – | – | Apr 15, 2026 |
| Steven H SteinCMO & Head of Late-Stage Dev. | Award | 39,049 | – | – | Apr 15, 2026 |
| Edmund HarriganDirector | Awardpre-set plan | 269 | $94.12 | $25K | Mar 31, 2026 |
| Paul J ClancyDirector | Awardpre-set plan | 265 | $94.12 | $25K | Mar 31, 2026 |
| Baker Bros. Advisors LpDirector, 10% owner | Award2 fills | 842 | – | – | Mar 31, 2026 |
| Matteo TrottaEVP, GM, Dermatology US | Tax withholding | 537 | $92.23 | $50K | Mar 25, 2026 |
| Pablo J CagnoniPresident, R&D | Option exercise2 fills | 18,667 | $63.07 avg | $1.2M | Mar 17, 2026 |
| Pablo J CagnoniPresident, R&D | Option exercise2 fills | 18,668 | $61.59 avg | $1.1M | Feb 19, 2026 |
Trades by members of Congress
1 member reported 0 buys and 1 sale since May 15, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Robert P. Bresnahan, Jr. R | Sold | $1,001–$15K | May 15, 2025 | May 31, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Oct 15, 2026
- Insider plans to sell 144 · Sep 15, 2026
- News filing: Other news 8-K · Aug 31, 2026
- Insider plans to sell 144 · Aug 19, 2026
- Insider plans to sell 144 · Aug 12, 2026
- Insider plans to sell 144 · Aug 5, 2026
- Insider plans to sell 144 · Aug 5, 2026
- Insider plans to sell 144 · Aug 3, 2026
- Insider plans to sell 144 · Jul 31, 2026
- Insider plans to sell 144 · Jul 31, 2026
- Quarterly report 10-Q · Jul 28, 2026
- News filing: Quarterly results 8-K · Jul 28, 2026
- Insider plans to sell 144 · Jul 16, 2026
- Insider plans to sell 144 · Jul 16, 2026
- Insider plans to sell 144 · Jul 15, 2026
- News filing: Other news 8-K · Jul 6, 2026
- News filing: Other news 8-K · Jun 22, 2026
- News filing: Shareholder vote results 8-K · Jun 9, 2026
- News filing: Other news 8-K · Jun 8, 2026
- Insider plans to sell 144 · Jun 4, 2026
- Insider plans to sell 144 · May 26, 2026
- Insider plans to sell 144 · May 19, 2026
- Shareholder meeting proxy DEF 14A · Apr 28, 2026
- Quarterly report 10-Q · Apr 28, 2026
- News filing: Quarterly results 8-K · Apr 28, 2026
About Incyte Corp.
Business description
- Industry
- Services-Commercial Physical & Biological Research
- Sector
- Industrial Applications and Services
- Headquarters
- Wilmington, DE
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC
- SEC company number (CIK)
- 879169
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.